Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OligoG inhalation crossover study in cystic fibrosis with chronic Pseudomonas aeruginosa colonization
2010-023090-19Phase 2Completed
- Sponsor
- AlgiPharma
- Start
- Feb 2011
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of OligoG in cystic fibrosis (CF) (2 arms), sponsored by AlgiPharma. Primary endpoint: Safety and local tolerability of multiple-dose inhaled OligoG. Started Feb 2011; status: completed.
02
Drugs
OligoG
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2010-023090-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023090-19.